Transaction DateRecipientSharesTypePriceValue
30th December 2020Santos Salvador Dada421Open or private sale$35.03$14,748.01
29th December 2020Santos Salvador Dada5,679Open or private sale$35.02$198,900.16
28th December 2020Santos Salvador Dada3,400Open or private sale$35.00$119,012.24
24th December 2020Santos Salvador Dada2,000Open or private sale$35.05$70,108.40
23rd December 2020Santos Salvador Dada3,000Open or private sale$35.01$105,018.60
22nd December 2020Santos Salvador Dada500Open or private sale$35.07$17,536.20
17th December 2020Mezerville Roberto De8,000Open or private sale$33.14$265,151.20
15th December 2020Mezerville Roberto De2,000Open or private sale$33.00$66,003.60
7th December 2020Mezerville Roberto De10,000Open or private sale$30.14$301,427.00
3rd December 2020Santos Salvador Dada4,915Open or private sale$27.28$134,099.88
Establishment Labs Holdings
Establishment Labs Holdings logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Establishment Labs Holdings, Inc. engages in the design, development, manufacture, and marketing of silicone breast implants. The company was founded by Juan Jose Chacon-Quiros in 2013.


Ticker: ESTA
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1688757
Employees: 602
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Inventory, Net: $29 M (0%)
Assets, Current: $136 M (42%)
Property, Plant and Equipment, Net: $16 M (0%)
Other Assets, Noncurrent: $360 Th (-2%)
Assets: $157 M (34%)
Accounts Payable, Current: $8 M (-19%)
Accrued Liabilities, Current: $11 M (0%)
Liabilities, Current: $21 M (-11%)
Long-term Debt, Excluding Current Maturities: $49 M (1%)
Other Liabilities, Noncurrent: $2 M (0%)
Liabilities: $75 M (-2%)
Common Stock, Value, Issued: $212 M (43%)
Common Stock, Shares, Issued: $24 M (0%)
Retained Earnings (Accumulated Deficit): $155 M (22%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $4 M (439%)
Treasury Stock, Value: $29 Th (0%)
Treasury Stock, Shares: $4 M (0%)
Stockholders' Equity (Parent): $82 M (0%)
Liabilities and Equity: $157 M (34%)
Revenue: $10 M (0%)
Gross Margin: $7 M (-68%)
Research and Development: $2 M (-63%)
Operating Income/Loss: $10 M (-44%)
Provision for income taxes: $194 Th (-54%)